Related Experiment Video
Updated: May 7, 2026
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
Efficacy of LNP@2DG-DON liposomal nanoparticles in tumor inhibition and immune activation
Jianang Li1,2,3, Jiale Feng1,2,3, Runjie Liu4
1Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Background:
Pancreatic cancer has poor prognosis, and immunotherapy efficacy is limited by PD-L1 stability via GFAT1-mediated glycosylation. We developed LNP@2DG-DON, a liposomal nanoparticle co-delivering glycolysis inhibitor 2DG and GFAT1 inhibitor DON, to enhance antitumor immunity and metabolic targeting.
Methods:
LNP@2DG-DON nanoparticles were synthesized using the thin-film dispersion method and characterized for size, stability, drug loading, and release profiles. In vitro studies assessed cytotoxicity, apoptosis, migration, and invasion in ASPC-1 and PANC-1 pancreatic cancer cell lines. In vivo efficacy was evaluated in a subcutaneous xenograft mouse model, measuring tumor growth, immune cell infiltration, and survival. Western blotting, flow cytometry, and immunohistochemistry were employed to analyze molecular and cellular mechanisms.
Results:
LNP@2DG-DON showed uniform size (100-120 nm), high drug loading (6.84-9.27%), and sustained release. It significantly reduced cell viability, induced apoptosis, and inhibited metastasis in vitro. In vivo, it suppressed tumor growth, prolonged survival, and increased CD8+/NK cell infiltration while reducing immunosuppressive cells. Mechanistically, it downregulated PD-L1/GFAT1 and activated pro-apoptotic pathways.
Conclusions:
The dual-targeting LNP@2DG-DON nanoparticle synergistically combines metabolic and immune modulation, demonstrating superior antitumor effects compared to single-agent therapies. This approach represents a promising strategy for pancreatic cancer treatment, warranting further clinical investigation.
Insights
A novel nanoparticle, LNP@2DG-DON, co-delivers metabolic inhibitors to enhance immunotherapy for pancreatic cancer. This dual-targeting approach shows superior antitumor effects and warrants further clinical investigation.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Immunotherapy
Background:
- Pancreatic cancer has a poor prognosis, with immunotherapy limited by PD-L1 stability.
- GFAT1-mediated glycosylation stabilizes PD-L1, hindering immune responses.
- Targeting tumor metabolism and immune checkpoints is crucial for effective treatment.
Purpose of the Study:
- To develop a novel nanoparticle, LNP@2DG-DON, for co-delivery of glycolysis and GFAT1 inhibitors.
- To enhance antitumor immunity and metabolic targeting in pancreatic cancer.
- To evaluate the synergistic effects of combined metabolic and immune modulation.
Main Methods:
- Liposomal nanoparticles (LNP@2DG-DON) synthesized via thin-film dispersion.
- In vitro assessment of cytotoxicity, apoptosis, and metastasis in pancreatic cancer cell lines.
- In vivo efficacy studies in xenograft mouse models, including tumor growth, immune infiltration, and survival analysis.
Main Results:
- LNP@2DG-DON demonstrated optimal size, drug loading, and sustained release.
- Significant reduction in cancer cell viability, apoptosis induction, and metastasis inhibition in vitro.
- Suppressed tumor growth, prolonged survival, enhanced CD8+/NK cell infiltration, and reduced immunosuppressive cells in vivo.
Conclusions:
- LNP@2DG-DON synergistically combines metabolic and immune modulation for superior antitumor effects.
- This dual-targeting nanoparticle strategy shows promise for pancreatic cancer treatment.
- Further clinical investigation of LNP@2DG-DON is warranted.
